Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00468117 · ClinicalTrials.gov registry record · Phase 3
Efficacy of Islet After Kidney Transplantation
A Phase 3 study of Type 1 Diabetes Mellitus, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 3
- Development phase
- 24
- Enrollment target
- 10
- Study locations
NCT00468117: Completed Phase 3 study of Type 1 Diabetes Mellitus, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT00468117 is a Phase 3 study of Type 1 Diabetes Mellitus that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 24 participants, below the 172-participant average among 112 other Type 1 Diabetes Mellitus trials with a reported enrollment target (86% lower). The trial reports 10 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00468117, a Phase 3 study of Type 1 Diabetes Mellitus, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 24 participants
- Enrollment target
- 10
- Study locations
Study Summary
Type 1 diabetes is an autoimmune disease in which the insulin-producing pancreatic beta cells are destroyed, resulting in poor blood sugar control. The purpose of this study is to assess the benefit of islet transplantation in type 1 diabetic (T1D) kidney transplant recipients.
Conditions Studied
Interventions
- BIOLOGICAL Etanercept
- PROCEDURE Islet transplantation
- BIOLOGICAL Antithymocyte Globulin
- BIOLOGICAL Daclizumab or Basiliximab
- BIOLOGICAL Allogenic human purified pancreatic islets
Study Locations (10)
Illinois
- Northwestern University - Chicago
- University of Illinois at Chicago - Chicago
California
- University of California, San Francisco - San Francisco
Florida
- University of Miami - Miami
Georgia
- Emory Universtiy - Atlanta
Massachusetts
- Massachusetts General Hospital - Boston
Minnesota
- University of Minnesota - Minneapolis
Pennsylvania
- University of Pennsylvania - Philadelphia
Wisconsin
- University of Wisconsin - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2007-01 |
| Est. Completion | 2017-07-05 |
| Phase | Phase 3 |
What the finished NCT00468117 record still lists
NCT00468117 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 172-participant average among 112 other Type 1 Diabetes Mellitus trials with a reported enrollment target (86% lower).
The record links to 1 condition, with Type 1 Diabetes Mellitus appearing as the primary indexed condition, and to 5 interventions - of which Etanercept is the first listed.
NCT00468117 lists 10 locations in 9 states (Illinois, California, Florida).
Frequently Asked Questions
What is clinical trial NCT00468117 about?
NCT00468117 is a clinical study titled "Efficacy of Islet After Kidney Transplantation". Type 1 diabetes is an autoimmune disease in which the insulin-producing pancreatic beta cells are destroyed, resulting in poor blood sugar control. The purpose of this study is to assess the benefit of islet transplantation in type 1 diabetic (T1D) kidney transplant recipients.
What is the current status of trial NCT00468117?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 24 participants. The study started on 2007-01. Estimated completion is 2017-07-05.
What conditions does trial NCT00468117 study?
This clinical trial studies the following conditions: Type 1 Diabetes Mellitus.
What interventions are being tested in trial NCT00468117?
The interventions under investigation include: Etanercept (BIOLOGICAL), Islet transplantation (PROCEDURE), Antithymocyte Globulin (BIOLOGICAL), Daclizumab or Basiliximab (BIOLOGICAL), Allogenic human purified pancreatic islets (BIOLOGICAL).
Who is sponsoring clinical trial NCT00468117?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00468117 being conducted?
This trial has 10 study locations across California, Florida, Georgia, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 1 Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00468117's enrollment target sits among peer trials
24 82nd of 112 higher than 29 of 112 other Type 1 Diabetes Mellitus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 1 Diabetes Mellitus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes
RECRUITING · Phase 3
-
Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol
ACTIVE NOT RECRUITING · Phase 3
-
A Phase III Study to Investigate if the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control in Patients Newly Diagnosed With Type 1 Diabetes
ACTIVE NOT RECRUITING · Phase 3
-
Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period
COMPLETED · Phase 3
-
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus
COMPLETED · Phase 3
-
Pediatric Diabetics Type 1 Using InsuPatch
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia